Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nectar Life Care Launches Affordable Anti-Diabetic Range of Medicines
Details : Dapnec (dapagliflozin) is a SGLT2 inhibitor small molecule drug candidate, which is indicated for the treatment of Type 2 diabetes.
Product Name : Dapnec
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2025
Lead Product(s) : Dapagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable